Just been digging into ADMA Biologics and their Asceniv story - there's something interesting building here that doesn't get enough attention.

Asceniv, their flagship intravenous immunoglobulin derived from plasma, is having a moment. We're talking 51% year-over-year revenue growth in 2025, hitting $363 million. That kind of drive isn't typical in the biotech space, especially for a company still in relatively early market penetration. The broader company hit $510.2 million in revenue last year, up 20% overall, but Asceniv is clearly the engine driving that growth.

What caught my eye is the supply side momentum. ADMA just expanded partnerships to access over 280 plasma collection sites, which addresses what's historically been the bottleneck in this space. They're using proprietary donor screening and specialized pooling techniques - combining standard plasma with RSV-antibody-rich plasma from specially screened donors. It's a technical moat that matters when you're competing for consistent supply.

The market opportunity still looks underexploited. Asceniv treats primary immunodeficiency disease and inherited immune deficiencies in adults and teens. Insurance coverage is improving, physician adoption is accelerating, and patient awareness is growing. Management sees this as still early stages of capturing a major market, which is a significant bullish signal if they're right.

On the numbers front, they're projecting $635 million in total revenue for 2026 and north of $775 million by 2027. If Asceniv maintains even half its current growth trajectory, that drive toward those targets looks achievable. The EPS estimates have tightened up too - consensus is now $0.96 for 2026 and $1.38 for 2027, which suggests the market is pricing in some of this momentum.

That said, there's real competition. Grifols and Takeda both have established positions in plasma therapeutics. Grifols has the distribution network advantage, while Takeda is pushing next-gen formulations like their 20% subcutaneous IG (TAK-881). ADMA needs to keep executing on supply and market share to maintain this growth drive.

Valuation-wise, the stock trades at 3.18x projected sales - still above the 1.98x industry average, so there's premium pricing baked in. The stock itself is down 37.9% over the past six months while the industry climbed 9.6%, which suggests either overreaction or justified caution depending on your view of execution risk.

The thesis here is straightforward: if ADMA can sustain Asceniv's growth trajectory and their supply chain holds up, this could be a meaningful revenue and earnings growth story through 2026-2027. But it's execution-dependent, and the valuation leaves limited room for disappointment. Worth watching if you're looking at biotech names with real commercial momentum.